UCB granted rights to Biogen's Tecfidera and other MS therapies in Asia
This article was originally published in Scrip
Executive Summary
Biogen Idec has granted Brussels-based firm UCB the commercialization rights for its portfolio of multiple sclerosis (MS) and hemophilia drugs in Asia.